roche glp 1 drug Baseline, Roche, Intellia, Eli Lilly: Readout Newsletter Roche's $2.7B weight-loss wager delivers

GLP-1-based therapies helped adults with overweight or obesity lose weight mainly by reducing fat mass and visceral adipose tissue, while lean body mass losses were generally modest

Acccording to the Route of Administration, the market is segmented into Parenteral, and Oral

In clinical trials, people using GLP-1 drugs lost an average of about 10 pounds more than people using a placebo

The inclusion of Akkermansia muciniphilaa microbe studied for its role in gut barrier health and metabolic signalingmakes this formula unique among microbiome supplements

The data were analyzed using both mean differences (MDs) and standardized mean differences (SMDs) with 95% CIs and odds ratios (ORs) with 95% CIs